Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Vesicular Transport Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for COPB2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | COPB2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Designed for PPI screening. |
View COPB2 Products |
| Gene Delivery | COPB2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and knockdown rescue assays. |
View COPB2 Products |
| Benchmark Ab | Anti-COPB2 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View COPB2 Products |
| Validator | COPB2 siRNA Set For knockdown verification and functional phenotypic assays. |
View COPB2 Products |
| Related Target A | ARF1 Small GTPase that recruits the COPI complex to membranes; key functional partner. |
View ARF1 Products |
| Related Target B | COPA Alpha subunit of the COPI coatomer complex; critical for specificity and off-target screening. |
View COPA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Screening | Recombinant COPB2 proteins with high purity (>95%) and verified sequence integrity. |
| Subfamily Off-Target Profiling | Homolog panel proteins (COPA, COPB1) strictly verified by mass spectrometry. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included. |
| False Positives | Validated siRNA sets included for target specificity and functional knockdown checks. |
Live COPB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for COPB2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to intracellular delivery modalities. COPB2 (Coatomer Protein Complex Subunit Beta 2) plays a pivotal role in retrograde vesicle transport from the Golgi apparatus to the endoplasmic reticulum. Because COPB2 overexpression is strongly correlated with tumor progression, cell cycle arrest, and apoptosis evasion in various cancers—including glioblastoma, colorectal cancer, and lung adenocarcinoma—it has emerged as a high-value oncology target. As first-generation therapies reach the clinic, the next wave of R&D is targeting intracellular protein-protein interactions (PPIs) and RNA interference (RNAi) pathways to selectively disrupt COPI vesicle formation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi / siRNA | Alnylam, Arrowhead, Wave Life Sciences | Solid Tumors, Glioblastoma | Target Knockdown Validation (Need validated siRNA and Lentiviral delivery) |
| Small Molecule (PPI) | Schrodinger, Arrakis, Intracellular PPI Specialists | Colorectal Cancer, Prostate Cancer | In vitro binding assays (Need high-purity, sequence-verified COPB2 recombinant protein) |
| PROTAC / Degraders | Arvinas, C4 Therapeutics | Refractory Solid Tumors | Degradation kinetics (Need benchmark antibodies and stable cell line models) |